TY - JOUR
T1 - Perspectives in immunotherapy
T2 - meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy)
AU - Ascierto, Paolo A.
AU - Bifulco, Carlo
AU - Ciardiello, Fortunato
AU - Demaria, Sandra
AU - Emens, Leisha A.
AU - Ferris, Robert
AU - Formenti, Silvia C.
AU - Galon, Jerome
AU - Khleif, Samir N.
AU - Kirchhoff, Tomas
AU - McQuade, Jennifer
AU - Odunsi, Kunle
AU - Patnaik, Akash
AU - Paulos, Chrystal M.
AU - Taube, Janis M.
AU - Timmerman, John
AU - Fox, Bernard A.
AU - Hwu, Patrick
AU - Puzanov, Igor
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-term survival with immunotherapy in various types of malignancy. Recurring observations with immuno-oncology agents include their potential for clinical application across a broad patient population with different tumor types, conventional and unconventional response patterns, durable responses, and immune-related adverse events. Despite the substantial achievements to date, a significant proportion of patients still fail to benefit from current immunotherapy options, and ongoing research is focused on transforming non-responders to responders through the development of novel treatments, new strategies to combination therapy, adjuvant and neoadjuvant approaches, and the identification of biomarkers of response. These topics were the focus of the virtual Immunotherapy Bridge (December 2nd–3rd, 2020), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer and are summarised in this report.
AB - Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evidence of the potential for long-term survival with immunotherapy in various types of malignancy. Recurring observations with immuno-oncology agents include their potential for clinical application across a broad patient population with different tumor types, conventional and unconventional response patterns, durable responses, and immune-related adverse events. Despite the substantial achievements to date, a significant proportion of patients still fail to benefit from current immunotherapy options, and ongoing research is focused on transforming non-responders to responders through the development of novel treatments, new strategies to combination therapy, adjuvant and neoadjuvant approaches, and the identification of biomarkers of response. These topics were the focus of the virtual Immunotherapy Bridge (December 2nd–3rd, 2020), organized by the Fondazione Melanoma Onlus, Naples, Italy, in collaboration with the Society for Immunotherapy of Cancer and are summarised in this report.
KW - Biomarkers
KW - Checkpoint inhibitors
KW - Combination therapy
KW - Immunotherapy
KW - Tumor microenvironment
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85107224369&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107224369&partnerID=8YFLogxK
U2 - 10.1186/s12967-021-02895-2
DO - 10.1186/s12967-021-02895-2
M3 - Article
C2 - 34078406
AN - SCOPUS:85107224369
SN - 1479-5876
VL - 19
JO - Journal of translational medicine
JF - Journal of translational medicine
IS - 1
M1 - 238
ER -